Monitoring Potential Side Effects Despite its overall safety profile, semaglutide GLP-1 does have potential adverse effects, including digestive problems such as constipation, diarrhea, nausea, and abdominal discomfort
That means no injections are required and it is suitable for long-term use as well
The incorporation of amyloid-related therapy either as an add-on or as a link to specific aspects of AD pathophysiology might become an important trend in clinical trials of new drugs in the future
On October 2, 2024, the FDA declared the tirzepatide shortage resolved
However, they did observe improvements in blood pressure, blood glucose levels, liver function, and a reduction in other medication use in the participants